CriticalPharmacokinetic enhancer (booster) for antiretroviral therapy×Antigout agents
Updated · Methodology
Mechanism
CYP3A4 is the main enzyme that metabolises colchicine, and the transporter P-glycoprotein (P-gp) pumps it out of cells (colchicine label, US Food and Drug Administration, FDA). Colchicine has a narrow therapeutic range and is extremely toxic in overdose (colchicine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Cobicistat is a strong CYP3A inhibitor and also inhibits P-gp (cobicistat SmPC, European Medicines Agency, EMA). The combination has not been studied, but the cobicistat SmPC expects colchicine levels to rise (cobicistat SmPC, EMA).
Symptoms
The first signs of colchicine poisoning are nausea, vomiting, abdominal pain and diarrhoea. High doses cause profuse diarrhoea and gastrointestinal bleeding (colchicine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). In severe poisoning, symptoms may appear after a delay of about 3 hours on average. After 24–72 hours, multi-organ failure, acute kidney failure, confusion and coma, myocardial depression and arrhythmias, a fall in all blood cells (pancytopenia) and respiratory failure develop (colchicine SmPC, AEMPS). Life-threatening and fatal colchicine toxicity at therapeutic doses has been reported with strong CYP3A4 inhibitors or P-glycoprotein inhibitors (colchicine label, US Food and Drug Administration, FDA).
Management
The combination is contraindicated. The Spanish summaries of product characteristics (SmPCs) of the original colchicine (1 mg and 0.5 mg tablets from one manufacturer) contraindicate colchicine during use of CYP3A4 or P-glycoprotein inhibitors and for 14 days afterwards (colchicine SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). According to its own SmPC, cobicistat inhibits both pathways (cobicistat SmPC, European Medicines Agency, EMA). The US label of colchicine 0.5 mg also contraindicates strong CYP3A4 inhibitors and P-glycoprotein inhibitors (colchicine label, US Food and Drug Administration, FDA). The cobicistat documents are less strict. Under the EU SmPC, the combination is contraindicated only in renal or hepatic impairment. With normal kidney and liver function, a lower colchicine dose may be needed (cobicistat SmPC, EMA). The US cobicistat label lists colchicine among its contraindications. Its interaction table, however, limits the contraindication to the same kidney and liver conditions and gives reduced-dose regimens for other patients (cobicistat FDA label). With moderate or strong CYP3A4 inhibitors or with P-glycoprotein inhibitors, the SmPCs of other colchicine manufacturers call for a lower maximum colchicine dose and close monitoring. In renal or hepatic impairment, they advise avoiding the combination whenever possible (colchicine SmPC of another manufacturer, AEMPS). At the first sign of nausea, vomiting, abdominal pain or diarrhoea, stop colchicine and seek emergency care (colchicine SmPC, AEMPS). If overdose is suspected, refer the person for immediate medical assessment, even without symptoms, and monitor them in hospital. There is no antidote, and haemodialysis does not remove colchicine. Within one hour of ingesting more than 0.1 mg per kilogram of body weight, consider oral activated charcoal (colchicine SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Colchicina Seid 0,5 mg (nº registro 78947), secciones 4.2, 4.3, 4.5 y 4.8 (2026)– AEMPS, CIMA, nº registro 78947, revisión 04/2026, secciones 4.2, 4.3, 4.5 y 4.8
- AEMPS: Ficha técnica: Colchicina Indoco 0,5 mg (nº registro 90154), secciones 4.2, 4.4 y 4.5 (2025)– AEMPS, CIMA, nº registro 90154, revisión 02/2025, secciones 4.2, 4.4 y 4.5
- FDA: Lodoco (colchicine) prescribing information (2026)– FDA, DailyMed setid ff06d68f-d65f-d097-e053-6294a90a7e5f, Agepha Pharma, revised 08/2026, sections 4 and 7 (Table 1)
- EMA: Ficha técnica: Cobicistat (EU/1/13/872), sección 4.5 (2026)– EMA, Tybost 150 mg (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 113872001, consultada 10/2026, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Colchicina Seid 1 mg (nº registro 33720), secciones 4.3, 4.4, 4.8 y 4.9 (2026)– AEMPS, CIMA, nº registro 33720 (Colchicina Seid 1 mg comprimidos, Seid S.A., autorizado desde 1960), revisión 04/2026, secciones 4.3, 4.4, 4.5, 4.8 y 4.9
- FDA: TYBOST (cobicistat) prescribing information (2026)– FDA, DailyMed setid 3784c35c-e87f-410c-900b-8fd6313c6010 (Gilead Sciences), versión 16 (SPL 10.02.2026, publicada 18.02.2026), secciones 4, 5.3, 7.1 y 7.3 (Table 7)